Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Qu, Changping; Sun, Guizhi; Yang, Shao-Qin; Tian, Jie; Si, Jin-Ge; Wang, Yifeng

doi:10.1097/md.0000000000005797

Cited by 3 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paclitaxel combined with carboplatin was recommended as a first-line chemotherapy strategy for ovarian cancer by National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines Network and National Comprehensive Cancer Network guidelines 1–3. Network meta-analyses have confirmed that paclitaxel plus carboplatin could improve progression-free survival (PFS) and overall survival (OS) compared with platinum alone 4 5. However, detailed implementation schedule (weekly or 3-weekly therapy) was not specified in these guidelines.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

Qiu

Dang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

IntroductionNetwork meta-analyses have confirmed that paclitaxel plus carboplatin could improve progression-free survival (PFS) and overall survival (OS) compared with platinum alone. However, detailed implementation schedule (weekly or 3-weekly therapy) was not specified in clinical practice guidelines. Evidence from studies is also inconsistent. We will conduct a systematic review and meta-analysis to evaluate the benefits and harms of weekly therapy and 3-weekly therapy of paclitaxel combined with carboplatin in women with ovarian cancer.MethodsWe will search PubMed, EMBASE and the Cochrane Library databases to include relevant randomised controlled trials comparing weekly therapy versus 3-weekly therapy of paclitaxel combined with carboplatin for women with ovarian cancer. Random-effects model will be used to pool data for patient-reported outcomes including survival rate, OS, PFS and adverse events. Grading of Recommendation, Assessment, Development and Evaluation approach will be used to rate the quality of evidence.Ethics and disseminationThis systematic review and meta-analysis will be based on published data and does not therefore require specific ethical approval or consent for participation. The results will be published in a peer-reviewed journal.OSF registration number10.17605/OSF.IO/GJUMA.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

Qiu

Dang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

show abstract

Molecular Markers for Treatment Response and Toxicity of Gemcitabine

Bhaskar

Lakkakula²

2019

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy

View full text Add to dashboard Cite

Nanomedicine review: clinical developments in liposomal applications

et al. 2019

View full text Add to dashboard Cite

Background Many conventional drugs exhibit poor pharmacokinetics, limited bioavailability and a high toxicity, all of which restrain their use. To overcome these issues and improve the therapeutic indexes of the drug, the emergent fields of nanotechnology and nanomedicine have made significant progress in detection, diagnosis and treatment of several diseases at clinical level (Li et al. 2014; Yingchoncharoen et al. 2016; Signorell et al. 2018). In fact, thanks to nanoparticles and liposomes, it has been possible to decrease the toxicity and improve the pharmacokinetics parameters, such as distribution, increased circulation time, targeted controlled release, increased intracellular concentration, and

show abstract

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Abstract: Supplemental Digital Content is available in the text

Cited by 3 publications

References 46 publications

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

Molecular Markers for Treatment Response and Toxicity of Gemcitabine

Nanomedicine review: clinical developments in liposomal applications

Contact Info

Product

Resources

About